WO2023019638A1 - 人原代急性髓系白血病细胞的培养基及培养方法 - Google Patents
人原代急性髓系白血病细胞的培养基及培养方法 Download PDFInfo
- Publication number
- WO2023019638A1 WO2023019638A1 PCT/CN2021/115503 CN2021115503W WO2023019638A1 WO 2023019638 A1 WO2023019638 A1 WO 2023019638A1 CN 2021115503 W CN2021115503 W CN 2021115503W WO 2023019638 A1 WO2023019638 A1 WO 2023019638A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- myeloid leukemia
- acute myeloid
- culture medium
- primary
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title claims abstract description 135
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title claims abstract description 133
- 239000001963 growth medium Substances 0.000 title claims abstract description 37
- 238000012136 culture method Methods 0.000 title claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 179
- 230000000694 effects Effects 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 239000003797 essential amino acid Substances 0.000 claims abstract description 15
- 101000932480 Homo sapiens Fms-related tyrosine kinase 3 ligand Proteins 0.000 claims abstract description 14
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims abstract description 14
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract description 14
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims abstract description 14
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims abstract description 14
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract description 14
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 14
- 102000052622 human IL7 Human genes 0.000 claims abstract description 14
- 102000055151 human KITLG Human genes 0.000 claims abstract description 14
- 235000020776 essential amino acid Nutrition 0.000 claims abstract description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000654 additive Substances 0.000 claims abstract description 9
- 230000000996 additive effect Effects 0.000 claims abstract description 7
- 238000011156 evaluation Methods 0.000 claims abstract description 6
- 229940116886 human interleukin-6 Drugs 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 53
- 239000006143 cell culture medium Substances 0.000 claims description 21
- 239000007640 basal medium Substances 0.000 claims description 15
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 7
- 238000007877 drug screening Methods 0.000 claims description 6
- 239000012091 fetal bovine serum Substances 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 239000012679 serum free medium Substances 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 229960005322 streptomycin Drugs 0.000 claims description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 3
- 229960003942 amphotericin b Drugs 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 238000012364 cultivation method Methods 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000013930 proline Nutrition 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 13
- 238000012216 screening Methods 0.000 abstract description 5
- 230000003321 amplification Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 description 20
- 239000000203 mixture Substances 0.000 description 17
- 230000035755 proliferation Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 230000004663 cell proliferation Effects 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- 102000055276 human IL3 Human genes 0.000 description 10
- 102000052611 human IL6 Human genes 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 8
- 239000012533 medium component Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 239000013630 prepared media Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102000041829 R-spondin family Human genes 0.000 description 1
- 108091078718 R-spondin family Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000013104 leukocyte disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Abstract
Description
Claims (5)
- 一种人原代急性髓系白血病细胞培养基,其特征在于,包含:谷氨酰胺添加剂、非必需氨基酸、人白介素-6、人白介素-7、人白介素-3、重组人FLT3 Ligand、重组人巨噬细胞集落刺激因子、和人干细胞因子。
- 如权利要求1所述的人原代急性髓系白血病细胞培养基,其特征在于,所述人原代急性髓系白血病细胞的培养基满足以下任意一项或多项或全部满足:(1)所述谷氨酰胺添加剂在培养基中的含量为0.5mM~4mM;(2)所述非必需氨基酸为选自甘氨酸、丙氨酸、天冬酰胺、天冬氨酸、谷氨酸、脯氨酸和丝氨酸中的一种或多种,所述非必需氨基酸在培养基中的含量为12.5μM~200μM;(3)所述人白介素-6在培养基中的含量为1.89ng/mL~17ng/mL;(4)所述人白介素-7在培养基中的含量为1.89ng/mL~51ng/mL;(5)所述人白介素-3在培养基中的含量为1.89ng/mL~153ng/mL;(6)所述重组人FLT3 Ligand在培养基中的含量为3ng/mL~81ng/mL;(7)所述重组人巨噬细胞集落刺激因子在培养基中的含量为1ng/mL~81ng/mL;(8)所述人干细胞因子在培养基中的含量为1ng/mL~81ng/mL。
- 如权利要求1或2所述的人原代急性髓系白血病细胞培养基,其特征在于,所述人原代急性髓系白血病细胞的培养基还包含基础培养基,所述基础培养基含有选自单核细胞无血清培养基和RPMI-1640的初始培养基、胎牛血清、以及选自链霉素/青霉素、两性霉素B和Primocin中的一种或多种的抗生素。
- 一种人原代急性髓系白血病细胞的培养方法,其特征在于:使用如权利要求1-3中任一项所述的人原代急性髓系白血病细胞培养基对人原代急性髓系白血病细胞进行培养。
- 一种人原代急性髓系细胞白血病的药物筛选或疗效评估方法,其包括以下步骤:(1)使用如权利要求4所述的人原代急性髓系白血病细胞的培养方法培养人原代急性髓系白血病细胞;(2)选定需要检测的药物并稀释成不同的浓度梯度;(3)对(1)中培养得到的细胞添加稀释后的所述药物,并进行细胞活性测试。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110959221.1 | 2021-08-20 | ||
CN202110959221.1A CN115896025A (zh) | 2021-08-20 | 2021-08-20 | 人原代急性髓系白血病细胞的培养基及培养方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023019638A1 true WO2023019638A1 (zh) | 2023-02-23 |
Family
ID=85239308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/115503 WO2023019638A1 (zh) | 2021-08-20 | 2021-08-31 | 人原代急性髓系白血病细胞的培养基及培养方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115896025A (zh) |
WO (1) | WO2023019638A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102220282A (zh) * | 2011-04-26 | 2011-10-19 | 广东省人民医院 | 从白血病细胞株分选白血病干细胞的方法 |
CN108553477A (zh) * | 2018-07-13 | 2018-09-21 | 大连理工大学 | 核苷类细胞分裂素在人急性髓性白血病m4型细胞中的应用 |
CN108865999A (zh) * | 2018-07-13 | 2018-11-23 | 大连理工大学 | 一类诱导分化试剂在人急性髓性白血病m2型细胞中的应用 |
CN111454896A (zh) * | 2020-04-10 | 2020-07-28 | 南京大学 | 一种提高间充质干细胞促进急性髓系白血病细胞分化能力的诱导方法 |
-
2021
- 2021-08-20 CN CN202110959221.1A patent/CN115896025A/zh active Pending
- 2021-08-31 WO PCT/CN2021/115503 patent/WO2023019638A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102220282A (zh) * | 2011-04-26 | 2011-10-19 | 广东省人民医院 | 从白血病细胞株分选白血病干细胞的方法 |
CN108553477A (zh) * | 2018-07-13 | 2018-09-21 | 大连理工大学 | 核苷类细胞分裂素在人急性髓性白血病m4型细胞中的应用 |
CN108865999A (zh) * | 2018-07-13 | 2018-11-23 | 大连理工大学 | 一类诱导分化试剂在人急性髓性白血病m2型细胞中的应用 |
CN111454896A (zh) * | 2020-04-10 | 2020-07-28 | 南京大学 | 一种提高间充质干细胞促进急性髓系白血病细胞分化能力的诱导方法 |
Non-Patent Citations (6)
Title |
---|
BOYER, M. W. ET AL.: "Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells", LEUKEMIA, vol. 14, 31 December 2000 (2000-12-31), pages 412 - 418, XP037783037, DOI: 10.1038/sj.leu.2401685 * |
CHAE HEE-DON, COX NICK, DAHL GARY V., LACAYO NORMAN J., DAVIS KARA L., CAPOLICCHIO SAMANTA, SMITH MARK, SAKAMOTO KATHLEEN M.: "Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways", ONCOTARGET, vol. 9, no. 4, 12 January 2018 (2018-01-12), pages 4301 - 4317, XP093036588, DOI: 10.18632/oncotarget.23794 * |
CHAPMAN ET AL., STEM CELL RESEARCH & THERAPY, vol. 5, 2014, pages 60 |
FEI YIWEN: "YTHDF2 Promotes the Growth of Chronic Myelogenous Leukemia as An m6A Reader Protein", MEDICINE & PUBLIC HEALTH, CHINESE SELECTED DOCTORAL DISSERTATIONS AND MASTER'S THESES FULL-TEXT DATABASES (MASTER'S), no. 2, 15 February 2021 (2021-02-15), XP093036590 * |
HANYANG LIN ET AL.: "Feeder-free and serum-free in vitro assay for measuring the effect of drugs on acute and chronic myeloid leukemia stem/progenitor cells", EXPERIMENTAL HEMATOLOGY, vol. 90, 2020, pages 52 - 64 |
SILVIA RAVERA ET AL., SCIENTIFIC REPORTS, vol. 10, 2020, pages 16519 |
Also Published As
Publication number | Publication date |
---|---|
CN115896025A (zh) | 2023-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021088119A1 (zh) | 原代乳腺上皮细胞培养基、培养方法及其应用 | |
WO2021184408A1 (zh) | 胃癌原代细胞的培养基及培养方法 | |
US11667894B2 (en) | Methods of primary tissue culture and drug screening using autologous serum and fluids | |
WO2021179354A1 (zh) | 原代肝癌细胞培养基、原代肝癌细胞培养方法及其应用 | |
US20160040120A1 (en) | In Vitro-Co-Culturesystem | |
Bellio et al. | Physiological and hypoxic oxygen concentration differentially regulates human c-Kit+ cardiac stem cell proliferation and migration | |
WO2023060774A1 (zh) | 宫颈癌类器官的培养基、及其培养方法和应用 | |
Tae et al. | Osteogenic potential of cell spheroids composed of varying ratios of gingiva‑derived and bone marrow stem cells using concave microwells | |
CN114181886A (zh) | 三维培养系统在巴马猪和食蟹猴肠上皮类器官中的应用 | |
WO2023019638A1 (zh) | 人原代急性髓系白血病细胞的培养基及培养方法 | |
WO2023019637A1 (zh) | 人原代急性淋巴白血病细胞的培养基及培养方法 | |
WO2022241845A1 (zh) | 肝癌原代细胞的培养基及培养方法 | |
WO2022227110A1 (zh) | 口腔癌原代细胞的培养基及培养方法 | |
WO2023004888A1 (zh) | 一种用于口腔癌类器官培养的培养基、及其培养方法和应用 | |
WO2023035299A1 (zh) | 一种用于肝癌类器官培养的培养基、及其培养方法和应用 | |
WO2023060764A1 (zh) | 胃癌原代细胞的培养基和培养方法 | |
WO2023060676A1 (zh) | 卵巢癌类器官的培养基、培养方法及其应用 | |
JP2022533012A (ja) | 細胞表現型を調節するための系および方法 | |
WO2024065883A1 (zh) | 一种用于鼻咽癌类器官培养的培养基、及其培养方法和应用 | |
WO2022160368A1 (zh) | 肠癌原代细胞的培养基及培养方法 | |
RU2418066C1 (ru) | Способ модификации пролиферативной активности и дифференцировочной потенции мультипотентных мезенхимальных стромальных клеток | |
WO2023060695A1 (zh) | 肝癌悬浮类器官的培养基和培养方法 | |
WO2023060696A1 (zh) | 卵巢癌原代细胞的培养基、培养方法及其应用 | |
WO2023060677A1 (zh) | 卵巢癌原代细胞的培养基、培养方法及其应用 | |
WO2023060709A1 (zh) | 食管癌类器官的培养基、培养方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21953875 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021953875 Country of ref document: EP Ref document number: 2024104393 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021953875 Country of ref document: EP Effective date: 20240320 |